Comparative Pharmacology
Head-to-head clinical analysis: PEDIATRIC ADVIL versus VIVLODEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PEDIATRIC ADVIL versus VIVLODEX.
PEDIATRIC ADVIL vs VIVLODEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis. This leads to anti-inflammatory, analgesic, and antipyretic effects.
COX-2 inhibitor; reduces prostaglandin synthesis via inhibition of cyclooxygenase-2 (COX-2) with minimal COX-1 inhibition.
Ibuprofen 200-400 mg orally every 4-6 hours as needed; maximum 1200 mg/day without prescription.
Once daily oral administration of 100 mg or 200 mg capsules. The recommended dose is 100 mg once daily; dose may be increased to 200 mg once daily if response is inadequate. Maximum daily dose: 200 mg.
None Documented
None Documented
Terminal elimination half-life is approximately 2-4 hours in children. Clinical context: rapid clearance; requires frequent dosing every 6-8 hours for sustained antipyretic/analgesic effect.
Terminal elimination half-life of the active moiety meloxicam is approximately 20 hours (range 12-24 h), allowing once-daily dosing in chronic pain.
Renal excretion of conjugated metabolites (glucuronides and sulfates) accounts for >90% of an administered dose, with <1% excreted unchanged. Biliary/fecal elimination is minimal (<5%).
VIVLODEX is a meloxicam NSAID prodrug. Following hydrolysis to meloxicam, excretion is primarily hepatic (metabolism) and renal (urine). Approximately 50% of meloxicam dose is excreted in urine as metabolites and <5% as parent drug; about 40% in feces. Biliary excretion is minor.
Category C
Category C
NSAID
NSAID